格隆汇1月29日丨医渡科技(02158.HK)公告，1月29日耗资72.8万港元回购12.2万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年1月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, demonstrating confidence in its intrinsic value and long-term development [1] Group 1: Share Buyback - On January 28, Yidu Tech announced a share buyback of 204,000 shares at approximately HKD 6 per share, costing around HKD 1.23 million [1] - The company has conducted share buybacks for three consecutive trading days, totaling approximately 709,000 shares repurchased and over HKD 4.2 million spent [1] Group 2: Business Progress - The number of insured individuals under the 2026 Beijing Universal Health Insurance program has surpassed 4.5 million, showcasing the company's operational strength and market recognition [1] - Yidu Tech has been the main operating platform for this project for five consecutive years, contributing to the multi-tiered medical security system in the capital [1] Group 3: International Collaboration and Recognition - The founder and chairman of Yidu Tech, Gong Rujing, attended the 2026 Winter Davos Forum, where a collaboration with Novartis Foundation and the Brunei Ministry of Health was announced for a cardiovascular disease prevention project called CARDIO4Cities [1] - Yidu Tech ranked first in the 2025 Medical Big Data Company Rankings for the seventh consecutive year, reflecting its strong technical foundation, mature product system, and extensive industry experience [1]

智通财经APP获悉，1月28日，医渡科技(02158)再度发布股份回购公告，宣布当日以每股约6港元的价格 回购20.4万股，耗资约123万港元。至此，公司已连续三个交易日密集实施回购操作，合计回购约70.9万 股，累计耗资超420万港元，持续以真金白银释放对公司内在价值的认可及长远发展的坚定信心。 除资本端积极动作外，公司主营业务亦传来进展。公司主运营的2026年度北京普惠健康保参保人数已突 破450万，作为连续五年担任该项目主运营平台的企业，医渡科技凭借专业的运营服务与技术赋能，持 续助力首都多层次医疗保障体系建设，进一步彰显了其业务实力与市场认可度。 此前消息显示，医渡科技创始人、董事长宫如璟近期受邀出席2026冬季达沃斯论坛，期间诺华基金会、 文莱卫生部与公司旗下EVYD公司三方合作消息宣布，将联合实施数智驱动的心血管疾病防控项目 CARDIO4Cities，进一步拓展国际合作版图。与此同时，行业权威榜单《2025医疗大数据企业排行榜》 正式揭晓，医渡科技凭借深厚的技术积淀、成熟的产品体系与丰富的行业落地经验，连续第七年斩获榜 首，持续领跑医疗大数据赛道。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2026年1月28日该公司斥资122.57万港元回购20.44万 股，回购价格为每股5.98-6.00港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年1月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

Core Viewpoint - Yidu Technology (2158.HK) is positioned as a leading enterprise in China's AI healthcare sector, focusing on the mission of making precision medicine accessible to everyone through technological innovation [1] Group 1: AI Technology and Applications - Yidu Technology has developed the YiduCore algorithm engine, creating a "data-algorithm-scenario" closed-loop system that enables efficient innovation and low-cost application of AI in healthcare [1] - The AI diagnostic assistant integrates into existing hospital workstations, preserving doctors' workflows while providing a one-stop intelligent support system [2] - The assistant enhances clinical decision-making by connecting medical evidence with individual patient data, significantly improving the efficiency of clinical decision-making processes [2] Group 2: Clinical Trial Recruitment - Yidu Technology has launched an AI-driven platform for clinical trial subject recruitment, addressing inefficiencies and high costs in the traditional recruitment process [3] - The platform utilizes an AI matching engine to understand complex clinical trial criteria and connects with vast clinical data, enabling precise identification of eligible subjects [3] - Compared to traditional methods, the platform reduces recruitment costs by 80% and increases patient enrollment speed by 15%, facilitating faster research progress [3] Group 3: Industry Ecosystem and Future Outlook - Yidu Technology has established a win-win ecosystem among pharmaceutical companies, medical institutions, and patients, showcasing the potential of new productivity in the healthcare sector [4] - The company aims to drive the transformation of healthcare services from "experience-driven" to "data-driven," making high-quality medical resources more accessible and equitable [4] - Future plans include deepening the integration of AI technology with medical scenarios and continuously optimizing products and solutions to inject ongoing intelligent momentum into the high-quality development of the healthcare industry [4]

Core Viewpoint - The company, Yidu Tech (02158), is actively engaging in share buybacks and has recently announced significant partnerships and achievements in the healthcare data industry [1] Share Buyback Activity - On January 27, Yidu Tech repurchased approximately 378,600 shares at a price of around HKD 6 per share, totaling nearly HKD 2.3 million [1] - The company has conducted buybacks for two consecutive days, accumulating a total of 505,000 shares repurchased and over HKD 3 million in total buyback amount [1] Industry Engagement and Partnerships - Yidu Tech's founder and chairman, Gong Rujing, participated in the 2026 Winter Davos Forum, engaging in high-level industry dialogues and meetings with global leaders [1] - At the forum, a significant collaboration was announced involving the Novartis Foundation, the Brunei Ministry of Health, and Yidu Tech's subsidiary, EVYD, to implement a smart-driven cardiovascular disease prevention project called CARDIO4Cities [1] Industry Recognition - Yidu Tech has been recognized as the top company in the "2025 Medical Big Data Company Rankings," marking its seventh consecutive year at the top, reflecting its strong technological foundation, mature product system, and extensive industry experience [1]

智通财经APP获悉，1月27日，医渡科技(02158)发布公告显示，公司当日以每股约6港元的价格回购 37.86万股，回购金额近230万港元，已连续两日回购，合计回购50.5万股，累计回购金额超300万港元。 与此同时，行业权威榜单的发布进一步印证了医渡科技的行业地位。《2025 医疗大数据企业排行榜》 正式揭晓，医渡科技凭借深厚的技术积淀、成熟的产品体系与丰富的行业落地经验，连续第七年斩获榜 首，持续领跑医疗大数据赛道。 消息面上，医渡科技创始人、董事长宫如璟近日受邀出席2026冬季达沃斯论坛，参与多场高级别行业对 话及闭门会议，并密集会见了全球政商学界领袖与合作伙伴。论坛上，诺华公司董事会主席Giovanni Caforio博士宣布一项重要合作：诺华基金会、文莱卫生部、医渡科技旗下EVYD公司将联合实施数智驱 动的心血管疾病防控项目——CARDIO4Cities。 ...

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, intending to repurchase approximately 378,600 shares at a cost of about HKD 2.27 million on January 27, 2026 [1]